Stock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook

Stock Track

Feb 20, 2025

Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.

The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.

Furthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.

In addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1109480944"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109480944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109480944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109480944","market":"us","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook","media":"Stock Track","content":"<p>Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.</p>\n\n<p>The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.</p>\n\n<p>Furthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.</p>\n\n<p>In addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-20 22:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.</p>\n\n<p>The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.</p>\n\n<p>Furthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.</p>\n\n<p>In addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1109480944","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109480944","pubTimestamp":1740061740,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Krystal Biotech Inc.  witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa . Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of po","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"股票轨迹Krystal Biotech Inc.(KRYS)因积极的盈利和分析师前景而盘前飙升5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.\nThe company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.\nFurthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.\nIn addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}